Corvus Pharmaceuticals price target raised to $24 from $21 at Ladenburg
The Fly

Corvus Pharmaceuticals price target raised to $24 from $21 at Ladenburg

Ladenburg raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $24 from $21 and keeps a Buy rating on the shares following the Q3 report. The firm increased its probability of sucess in soquelitinib’s peripheral T-cell lymphoma indication to 80%, viewing the chemotherapy arm as a relatively easy comparator.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App